NIH begins Phase I trial of DS-Cav1 to treat respiratory syncytial virus

The National Institutes of Health (NIH) in the US has begun the Phase I clinical trial (VRC 317) of an investigational vaccine DS-Cav1 for the treatment of respiratory syncytial virus (RSV).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news